• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

News & Events

  • Print
  • Share
  • E-mail

Section Contents Menu

Newsroom

FDA NEWS RELEASE

 
For Immediate Release: Sept. 18, 2012
Media Inquiries: Sarah Clark-Lynn, 301-796-9110, sarah.clark-lynn@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA
 
En Español
 

FDA issues Safety Alert on Intestinomicina, drug product marketed as treatment for infectious diarrhea

 
The U.S. Food and Drug Administration is warning consumers not to use Intestinomicina, a drug product manufactured in El Salvador and marketed as a treatment for infectious diarrhea and acute gastrointestinal infections. Consumers who have purchased this product should immediately stop taking it and consult with a health care provider.
 
Intestinominica contains the prescription drug ingredient, chloramphenicol. Oral forms of chloramphenicol were formally withdrawn from the United States market in July 2012 due to the risk of serious and life threatening injuries. 
 
Intestinomicina is labeled primarily in Spanish and lists the ingredient as “chloramfenicol palmitato,” or chloramphenicol in English, on the label. It can be found in tablet and liquid forms and is manufactured by Laboratorios Lopez. The product has been found in international grocery stores in the United States that feature South and Central American specialty foods and products.
 
The most serious and life-threatening injury associated with oral chloramphenicol treatment is bone marrow toxicity, which occurs when the body does not produce enough red blood cells, white blood cells, and/or platelets. Certain types of bone marrow toxicity are reversible; however, in rare circumstances it can lead to death. Patients with anemia, low white or red blood cell count, or decreased blood platelets may be at a greater risk of death or serious injury. 
 
The product label also lists antibacterial ingredients including neomycin, an antibiotic often found in topical medications, and sulfonamides, sometimes called sulfa drugs. Neomycin and sulfa drugs have the potential to cause a variety of adverse reactions, ranging from rashes and hives, to severe and life-threatening reactions.   
 
Intestinomicina may also interact with other medications consumers may be taking. 
   
Health care professionals and consumers are encouraged to report any adverse events related to Intestinomicina to FDA’s MedWatch Safety Information and Adverse Event Reporting Program:
 
  • online at www.fda.gov/Medwatch/report.htm;
  • by phone at 800-FDA-1088 (800-332-1088); or,
  • by returning FDA form 3500, available on the MedWatch “Download Forms” page by mail to the address on the pre-addressed form or by fax at 800-FDA-0178.
 
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
 
 Intestonomicina Suspension      Intestonomicina Tabletas
# # #
 
Read our Blog: FDA Voice
 
Visit the FDA on Facebook disclaimer icon , Flickr disclaimer icon , YouTube disclaimer icon  and Twitter disclaimer icon   
 
RSS Feed for FDA News Releases